Business Context and Reporting Period
Company: Wilson Greatbatch Technologies, Inc. (Note: Input metadata referenced "Integer Holdings Corp," but the filing text identifies the registrant as Wilson Greatbatch Technologies, Inc.)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2004 (Fiscal year ends the Friday nearest December 31).
Business Overview: The Company operates two segments: Implantable Medical Components (IMC), manufacturing batteries and components for pacemakers and defibrillators, and Electrochem Power Solutions (EPS), producing high-performance batteries for commercial applications.
Key Financial Metrics
| Metric (in thousands) | Q2 2004 | Q2 2003 | 6 Months 2004 | 6 Months 2003 |
|---|---|---|---|---|
| Sales | $52,942 | $55,802 | $108,467 | $110,659 |
| Gross Profit | $23,818 | $23,217 | $46,993 | $46,030 |
| Gross Margin | 45.0% | 41.6% | 43.3% | 41.6% |
| Operating Income | $7,708 | $9,546 | $18,081 | $19,223 |
| Net Income | $4,733 | $4,952 | $11,352 | $10,989 |
| Diluted EPS | $0.22 | $0.23 | $0.53 | $0.51 |
| Cash & Equivalents (End of Period) | $79,851 | $99,474 | $79,851 | $99,474 |
| Working Capital | $134,762 | N/A | $134,762 | N/A |
| Long-Term Debt (Convertible Notes) | $170,000 | $170,000 | $170,000 | $170,000 |
Note: Working Capital calculated as Current Assets ($155,076) minus Current Liabilities ($20,314).
Material Changes vs. Prior Period
- Revenue Decline: Sales decreased 5% in Q2 2004 compared to Q2 2003, driven primarily by a 7% volume decrease and 2% price decrease in the IMC segment due to reduced orders from one major Cardiac Rhythm Management (CRM) customer.
- Margin Expansion: Despite lower sales, Gross Margin improved to 45.0% (from 41.6%) due to Six Sigma/lean manufacturing initiatives and favorable product mix.
- Operating Expenses: "Other operating expense" spiked to $2.96 million in Q2 2004 (vs. $77k in Q2 2003) due to a $2.0 million charge for patent acquisition and $0.8 million in severance costs from a 7% workforce reduction.
- Acquisition Impact: The Company acquired NanoGram Devices Corporation (NDC) in March 2004 for $45.6 million, adding $0.4 million per quarter to amortization expenses.
- Cash Flow: Net cash provided by operating activities was $11.9 million for the six months ended June 30, 2004, down from $19.8 million in the prior year period. Net cash used in investing activities was $52.2 million, primarily due to the NDC acquisition and capital expenditures.
Guidance, Outlook, and Risks
- Outlook: Management anticipates continued capital spending of $32.0 million to $37.0 million for the remainder of 2004 for new manufacturing facilities (Alden, NY and Tijuana, Mexico) and ERP implementation.
- New Business: Signed a long-term agreement with a major CRM manufacturer for value-added sub-assembly, with sales expected to commence in Q2 2005.
- Cost Structure: The recent workforce reduction is expected to eliminate approximately $8.0 million from the ongoing annual cost structure.
- Risks & Contingencies:
- Customer Concentration: Significant dependence on a limited number of customers; a major customer reduced anticipated orders for the balance of 2004.
- Accounting Standards: Pending EITF Issue 04-8 regarding contingent convertible debt may require retroactive restatement of diluted EPS, potentially increasing dilution.
- Legal: No material legal proceedings reported, though the company is a party to various actions in the normal course of business.
Investor Verification Checklist
- Customer Concentration: Verify the extent of the order reduction from the major CRM customer and the timeline for recovery.
- Capital Expenditures: Confirm the progress and cost overruns, if any, regarding the new facilities in Alden, NY, and Tijuana, Mexico.
- Integration of NDC: Assess the commercial viability and integration progress of the NanoGram Devices acquisition and its contribution to future revenue.
- Convertible Notes: Review the terms of the $170 million convertible subordinated notes and the potential impact of EITF Issue 04-8 on future earnings per share.
- Patent Strategy: Evaluate the strategic value of the $2.0 million patent acquisition relative to the removal of obstacles for wet tantalum technology adoption.